Adaptin Bio (APTN) Change in Accured Expenses (2023 - 2026)

Adaptin Bio has disclosed Change in Accured Expenses across 4 years of filings, most recently posting $256901.0 for Q1 2026.

• Quarterly Change in Accured Expenses rose 1256.68% year-over-year to $256901.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252155.0 (down 70.59% YoY) and the FY2025 annual result came in at $14190.0, down 98.33% from the prior year.
• Change in Accured Expenses grew to $256901.0 in Q1 2026, from -$4746.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $787551.0 in Q4 2024 and bottomed at -$504977.0 in Q3 2024.
• The 4-year median for Change in Accured Expenses is $15916.5 (2024), against an average of $136745.0.
• Year-over-year, Change in Accured Expenses surged 2868.97% in 2024 and tumbled 100.85% in 2025.
• Adaptin Bio's Change in Accured Expenses stood at -$28442.0 in 2023, then surged by 2868.97% to $787551.0 in 2024, then sank by 100.6% to -$4746.0 in 2025, then soared by 5513.0% to $256901.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $256901.0, -$4746.0, and $18936.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.